云集 (YJ.US) 2025年第四度业绩电话会
文章语言：
简
繁
EN
Share
Minutes
原文
会议摘要
The company highlights progress in the organic and healthy living market, achieving 159 million RMB in total revenue with a 70% reduction in net loss. Despite a revenue decline from 183.8 million RMB, the core business shows health growth. Operating expenses significantly decreased, leading to a minimal operational loss. The company reaffirms its commitment to efficiency and growth, aiming to promote healthier lifestyles in China.
会议速览
Yog's Forward-Looking Earnings Call for H2 2025A reminder of forward-looking statements' risks, with Yog's leadership discussing 2025 H2 earnings, highlighting legal disclaimers and market uncertainties.
Yun's Earnings Call: Advancing Organic Healthy Living & Strengthening Sales Channels in 2025The dialogue highlights a company's dedication to organic healthy living, strategic enhancements in premium products, customer loyalty, and sales channel expansion, detailing financial and strategic progress for the second half of 2025.
2025 Q3: Revenue Growth, Efficiency, & Core Business DevelopmentIn H2 2025, the company achieved 159M RMB revenue, with merchandise sales up 0.16% from H2 2024. Net profit fell by 70%, attributed to strategic, operational, and financial improvements. A 69.7% purchase repurchase rate underscores user loyalty, supporting ongoing core business growth and efficiency enhancements.
Expanding Health Strategy with Organic Food and Medicine Mology ProductsThe company continues to advance its health strategy by aligning with China's International Health Strategy, focusing on organic foods and health products that meet consumer needs. By 2025, five products exceeded 10 million RMB in sales, reflecting growing consumer demand for health and wellness. The portfolio of food-medicine homology products is being expanded to cater to this trend.
Revolutionizing Health with Polygonal Term: Record Sales and Future ExpansionPolygonal Term, launched in Q4 2025, achieved record sales of 18 million RMB by year-end, highlighting its success in health-focused products. The company plans to expand its food-medicine homology range, enhancing health and wellness offerings to meet growing consumer demands.
Value-Driven Strategy Fuels Market Growth and Product DemandA strategic focus on quality and affordability has bolstered sales, with notable increases in poly peptide and cleaning products, underscoring the success of a forward-thinking value-for-money approach.
Transforming to a Product-Experience Platform: Enhancing User Engagement and TrustBy offering transparent supply chain experiences and interactive services like the Buckle Powder Trace tool, the company has successfully transitioned from a product sales platform to a comprehensive product-experience platform, enhancing user engagement, loyalty, and brand trust.
Strategic Growth and Efficiency: Activating User Base and Expanding Channels for Sustainable DevelopmentThe dialogue emphasizes a strategy focused on strengthening the core business through targeted user activation, expanding offline channels, and maintaining a commitment to organic living, aiming for balanced growth and efficiency.
2025 Q2 Financials: Revenue Decline, Cost Optimization, and Strategic Focus on Health ProductsDespite a challenging market, the company reported a 15.3% year-over-year revenue drop to $158.7M in Q2 2025, primarily due to strategic adjustments in the marketplace business. Total cost of revenues increased by 3.2% to $92.7M, driven by merchandise sales. The company optimized operations, reducing fulfillment, sales & marketing, technology, and administrative expenses significantly, leading to a 44% decrease in total operational expenses to $112.4M. These efforts resulted in a narrowed loss from operations, reflecting improved efficiency and strategic focus on health products.
2025 Financial Review: Improved Profitability, Optimized Capital, and Strategic Focus on Long-Term GrowthThe dialogue discusses a narrowing net loss per share, strong liquidity, and effective operational execution leading to improved financial health. It highlights strategic focus on market growth, cautious consumer sentiment, and selective branding, aiming for break-even and sustainable long-term growth.
要点回答
Q：What are the key financial results for the company in the second half of 2025?
A：In the second half of 2025, the company achieved total revenue of around 159 million RMB, with merchandise sales revenue at 120.58 million RMB, a 0.16% increase compared to the same period in 2024. The net loss significantly decreased from 150 million RMB to 33 million RMB, representing a 70% reduction. The company maintained a high purchase repurchase rate of 69.7%, reflecting the effectiveness of disciplined product selection and operational execution.
Q：What is the impact of the company's disciplined product selection and operational execution?
A：The company's disciplined product selection and operational execution have led to growing effectiveness, with an improvement in the quality and efficiency of the company's development continuing.
Q：How did the company's core business segments progress in the second half of 2025?
A：In the second half of 2025, the company firmly continued to cultivate its core business segment and achieved phased progress, focusing on advancing its health strategy and building a distinctive portfolio of food and medicine homology products.
Q：What are the examples of successful organic food and health products from 2025?
A：Examples of successful organic food and health products from 2025 include Yachay Lake Perry, probiotic balls, light streaming coffee, organic milk, and by and free drying the buck power.
Q：What are the examples of how the company's portfolio of food and medicine homology products expanded in 2025?
A：The company expanded its portfolio of food and medicine homology products in 2025 with the launch of the 'Jihu polygon', a natural and health-focused product that quickly became one of the company's most popular products, supported by premium ingredients and refined processing techniques.
Q：How did the company's value-for-money strategy perform in 2025?
A：The company's value-for-money strategy performed well in 2025, establishing and strengthening its market position. It met consumers' core demand for quality products at attractive prices, with a 20% year-over-year increase in sales of three-year poly peptide and a 72% year-over-year increase in sales of the derived cleaning moves.
Q：What was the outcome of the trace programs organized by the company?
A：The trace programs organized by the company had a strong outcome, continually strengthening trust in the products. Participation in these trace programs grew, attracting an increased number of members.
Q：How did the company enhance its key therapy experience and what does it contribute to?
A：The company enhanced its key therapy experience by providing services that form a solid foundation for broader consumer recognition of the medicine technology products. This enhances user participation and brand, along with emotional connections between users and the platform.
Q：What is the company's approach to customer acquisition and growth?
A：The company's approach to customer acquisition and growth involves consolidating the existing user base while actively exploring diversifying customer acquisition channels. This is to ensure balanced growth with efficiency and support the company's sustainable development.
Q：How were existing users activated and what were the results?
A：Existing users were activated through targeted operational initiatives such as repurchase invitations to over 50,000 users, resulting in 42.4% placing an order on the platform. The pilot initiative delivered strong activation and conversion results, unlocking the commercial value of the existing user base.
Q：What are the priorities for Link in the year ahead?
A：The priority for Link in the year ahead is to remain committed to its strategic positioning as a global leader in organic living, serving as the new growth engines through products and experiences, with efficiency and growth as core priorities.
Q：How did the company's total revenues for the second half of 2025 compare to the same period of 2024?
A：The total revenues for the second half of 2025 were 158.7 million, compared to 183.8 million a year ago, indicating a decrease of 3.2 million, or 0.6% compared to the same period of 2024.
Q：How did fulfillment, sales and marketing, and technology and content expenses change compared to the prior year?
A：Fulfillment expenses decreased to 30.3 million from 30.6 million a year ago, sales and marketing expenses were 42.6 million compared to 49.5 million a year ago, and technology and content expenses were 13 million compared to 20.1 million a year ago.
Q：What was the impact of the decrease in general and administrative expenses?
A：General and administrative expenses decreased to 33.5 million from 96.9 million a year ago, primarily driven by lower impairment to online live, loss for credit losses, and reduced personal cost resulting from a reduction in handouts. This indicates a strategic investment in sales and marketing for offline channel development and a reduction in other expenses.
Q：How did the level of loss from operations change from the prior year?
A：The loss from operations decreased to 40 thousandths million from 103.9 million a year ago, reflecting continuous improvement in operating efficiency and progress towards financial suitability. The net loss was 30.22 million compared with 115.1 million a year ago, showing a significant reduction.
Q：What does the continued level of loss reflect about the company's strategic focus?
A：The continued level of loss reflects the company's strategic focus on organic and healthful offerings and the effective experience provided to users.
Q：How did the company's cash and cash equivalents change from December 31, 2024 to December 30, 2025?
A：The company had a total of 216.1 million in cash, cash equivalents, and short-term investments on its balance sheet as of December 30, 2025, compared to 242.8 million at December 31, 2024, indicating a decrease of 26.7 million.
Yunji, Inc.
Follow
